⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

August 15, 2025Open Access

Figure S6 from MYLK-AS1 Enhances Glutamine Metabolism to Promote EGFR Inhibitor Resistance in Non–Small Cell Lung Cancer

Tianyu Qu Lei Song Jiali Xu Xiyi Lu Dandan Yin Jiali Dai Chen Zhang Renhua Guo Erbao Zhang

View Full Paper

Ask AI

Bookmark

Share

Key Points

MYLK-AS1 enhances glutamine metabolism and promotes resistance to EGFR inhibitors in non-small cell lung cancer.
Key evidence shows that METTL3-mediated m6A modification is crucial for MYLK-AS1 activation in TKI resistance.
Analysis indicates that MYLK-AS1 is linked to glutamine metabolism and resistance mechanisms in lung cancer.
The findings suggest that targeting MYLK-AS1 could help manage resistance to EGFR inhibitors in patients with non-small cell lung cancer.

Implication

Observational analysis highlights the role of MYLK-AS1 and m6A modification in TKI resistance in non-small cell lung cancer.

Abstract

METTL3-mediated post-transcriptional m6A modification contributes to the activation of MYLK-AS1 in TKI resistance of NSCLC.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Qu et al. (2025) studied this question.

synapsesocial.com/papers/68af59d2ad7bf08b1eade1f1 https://doi.org/10.1158/0008-5472.29919042

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Figure S5 from MYLK-AS1 Enhances Glutamine Metabolism to Promote EGFR Inhibitor Resistance in Non–Small Cell Lung Cancer2025
2Figure S4 from MYLK-AS1 Enhances Glutamine Metabolism to Promote EGFR Inhibitor Resistance in Non–Small Cell Lung Cancer2025
3Figure S10 from MYLK-AS1 Enhances Glutamine Metabolism to Promote EGFR Inhibitor Resistance in Non–Small Cell Lung Cancer2025
4Figure S7 from MYLK-AS1 Enhances Glutamine Metabolism to Promote EGFR Inhibitor Resistance in Non–Small Cell Lung Cancer2025
5Figure S2 from MYLK-AS1 Enhances Glutamine Metabolism to Promote EGFR Inhibitor Resistance in Non–Small Cell Lung Cancer2025